Akari TherapeuticsAKTX
Market Cap: 49.9M
About: Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
Employees: 12
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
0% less ownership
Funds ownership: 0% [Q4 2023] → 0% (-0%) [Q1 2024]
11% less funds holding
Funds holding: 9 [Q4 2023] → 8 (-1) [Q1 2024]
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
63% less capital invested
Capital invested by funds: $892K [Q4 2023] → $326K (-$565K) [Q1 2024]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q4 2023] → 0 (-1) [Q1 2024]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Research analyst outlook
We haven’t received any recent analyst ratings for AKTX.